In addition, frequencies of mutation in BCR-ABL kinase domain appear to increase and induce resistance to tyrosine kinase inhibitors as CML progresses [27]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.